ReNeuron Group plc
OTC: RNUGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iain Gladstone Ross
- Employees
- 26
- Headquarters
- Pencoed, United Kingdom
- IPO year
- 2007
- Market cap
- $62.9K
- Website
- https://www.reneuron.com
Loading RNUGF…
Loading profile data…Frequently asked questions about RNUGF
What does ReNeuron Group plc (RNUGF) do?
ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progr...
Where does RNUGF trade?
ReNeuron Group plc (RNUGF) trades on the Other OTC.
What sector is RNUGF in?
ReNeuron Group plc (RNUGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ReNeuron Group plc?
Iain Gladstone Ross is the chief executive officer of ReNeuron Group plc (RNUGF).
Where is ReNeuron Group plc headquartered?
ReNeuron Group plc is headquartered in United Kingdom.
Does RNUGF pay a dividend?
ReNeuron Group plc (RNUGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNUGF go public?
ReNeuron Group plc (RNUGF) completed its initial public offering in 2007.